Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology)

Senl_B19自体T细胞疗法（河北森朗）

Report date: 2025/01/14 20:00:08

Base Information

Drug NameAnti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology)
Drug Alias Name抗CD19 CAR-T细胞疗法（河北森朗）anti-CD19 CAR T-cell therapy (B-cell maligancy)Autologous CAR-T (Hebei Senlang Biotechnology)SENL-B19S1904 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesMultiple MyelomaLymphoma, B-Cell +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsMultiple MyelomaLymphoma, B-CellLymphoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A